Your browser doesn't support javascript.
loading
Intracoronary sarcoplasmic reticulum calcium-atpase gene therapy in advanced heart failure patients with reduced ejection fraction: a prospective cohort study
Zhang, Jianfeng; Hu, Guojin; Yang, Shengyong.
  • Zhang, Jianfeng; Second Rehabilitation Hospital of Shanghai. Cardio-Pulmonary Rehabilitation Inpatient Area. CN
  • Hu, Guojin; Second Rehabilitation Hospital of Shanghai. Cardio-Pulmonary Rehabilitation Inpatient Area. CN
  • Yang, Shengyong; Second Rehabilitation Hospital of Shanghai. Cardio-Pulmonary Rehabilitation Inpatient Area. CN
Clinics ; 75: e1530, 2020. tab, graf
Article in English | LILACS | ID: biblio-1089607
ABSTRACT

OBJECTIVE:

Heart failure is a progressive and debilitating disease. Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy may improve the function of cardiac muscle cells. This study aimed to test the hypothesis that intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy can improve outcomes and reduce the number of recurrent and terminal events in advanced heart failure patients with reduced ejection fraction.

METHODS:

A total of 768 heart failure patients with reduced ejection fraction and New York Heart Association classification II to IV were included in this prospective cohort study. Patients either underwent intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy (CA group, n=384) or received oral placebo (PA group; n=384). Data regarding recurrent and terminal event(s), treatment-emergent adverse effects, and outcome measures were collected and analyzed.

RESULTS:

After a follow-up period of 18 months, intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy reduced the number of hospital admissions (p=0.001), ambulatory treatments (p=0.0004), and deaths (p=0.024). Additionally, intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy improved the left ventricular ejection fraction (p<0.0001) and Kansas City Cardiomyopathy Questionnaire score (p<0.0001). The number of recurrent and terminal events/patients were higher in the PA group than in the CA group after the follow-up period of 18 months (p=0.015). The effect of the intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy was independent of the confounding variables. No new arrhythmias were reported in the CA group.

CONCLUSIONS:

Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy reduces the number of recurrent and terminal events and improves the clinical course of advanced heart failure patients with reduced ejection fraction.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Sarcoplasmic Reticulum / Heart Failure Type of study: Controlled clinical trial / Etiology study / Observational study / Risk factors Limits: Female / Humans / Male Language: English Journal: Clinics Journal subject: Medicine Year: 2020 Type: Article Affiliation country: China Institution/Affiliation country: Second Rehabilitation Hospital of Shanghai/CN

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Sarcoplasmic Reticulum / Heart Failure Type of study: Controlled clinical trial / Etiology study / Observational study / Risk factors Limits: Female / Humans / Male Language: English Journal: Clinics Journal subject: Medicine Year: 2020 Type: Article Affiliation country: China Institution/Affiliation country: Second Rehabilitation Hospital of Shanghai/CN